

**CURRICULUM VITAE
SHALINI KULASINGAM**

Academic Rank: Associate Professor (with tenure)
Division of Epidemiology and Community Health
School of Public Health
University of Minnesota

Degrees Awarded

Degree	Institution	Date Degree Granted
A.B.	Bryn Mawr College, Bryn Mawr, PA	1989
M.P.H	University of California, Los Angeles, Los Angeles, CA Epidemiology	1992
Ph.D.	University of Washington, Seattle, WA Epidemiology Dissertation Advisor: Dr. Laura Koutsky, Professor	2000

Employment

2012-Present	Associate Professor (with tenure), Division of Epidemiology and Community Health, University of Minnesota, MN
2008-2012	Assistant Professor, Division of Epidemiology and Community Health, University of Minnesota, MN
2006-2008	Assistant Professor, Department of Obstetrics and Gynecology
2004-2008	Senior Fellow, Duke Center for Clinical Health Policy and Research, Duke University, NC
2004-2006	Research Assistant Professor, Department of Obstetrics and Gynecology, Duke University, NC
2001-2004	Research Associate, Department of Obstetrics and Gynecology, Duke University, NC
2001-2004	Fellow, Duke Center for Clinical Health Policy and Research, Duke University, NC

RESEARCH AND SCHOLARSHIP

Honors and Awards

1993	Rotary International Fellow, University of British Columbia, BC, Canada
1995	Department Research Assistant, Department of Epidemiology, University of Washington, Seattle, WA
1996	Multidisciplinary International Research and Training Fellowship, University of Washington, Seattle, WA
1999	Student Workshop, Society for Epidemiologic Research, Baltimore, MD
2000	NIH Student Travel Award, 18 th International Papillomavirus Conference, Barcelona, Spain
2001	Post-Doctoral Fellow Travel Award, HPV Vaccine Conference, Cambridge, England
2002	Outstanding Presentation, 20 th International Papillomavirus Conference, Paris, France
2010	Highest graded review conducted for Annals of Internal Medicine

Journal Reviewer

Annals of Internal Medicine
Medical Decision Making
Journal of the American Medical Association
Journal of Medical Screening
PLoS Medicine
International Journal of Cancer
Journal of the Canadian Medical Association
New England Journal of Medicine
Vaccine

Research and Training Grants

Received at the University of Minnesota

1. Co-Investigator. PI: John Hughes, Assistant Professor, Division of Biostatistics, School of Public Health. NCI-R03. 2014-2016.
2. Sub-contract PI. PI: George Sawaya, Professor, Obstetrics, Gynecology and Reproductive Sciences and Epidemiology & Biostatistics University of California, San Francisco). Using comparative effectiveness analyses to optimize cervical cancer screening. NCI- 1R01CA169093-01A1. 2013-2017.
3. Principal Investigator (Multiple PI: Kiviat, Professor, Pathology, University of Washington). Cytology vs. at home HPV testing. NCI- R01-CA 157469. \$2,498,561. 2011-2016
4. Principal Investigator. AHRQ. Update of decision modeling for the United States Preventive Services Task Force. \$166,124 2010-2011
5. Co-Investigator. PI: Karen Kuntz. Professor, Division of Health Policy, School of Public Health, UMN. AHRQ. Decision modeling for guideline development. \$450 000. 2009-2010
6. Principal Investigator. National Cancer Institute. Administrative Supplement. \$74,774. 2009-2011
7. Principal Investigator. National Institutes of Allergy and Infectious Diseases – R03. New Approaches to Cervical Cancer Prevention in India. \$224,730. 2009-2012
8. Principal Investigator. Singapore Ministry of Health. Review of a Markov model-based economic evaluation of HPV vaccination to prevent cervical cancer in Singapore. \$32,000, 2009

Received at Duke University

1. Principal Investigator. Agency for Health Research and Quality. Cervical cancer screening decision analysis for the US PSTF guidelines. \$70,000. 2007-2008
2. Co-Investigator. PI: Gillian Sanders. Agency for Healthcare Research and Quality. Use of Bayesian techniques for randomized clinical trials. \$150,000. 2007-2008
3. Principal Investigator. National Cancer Institute. KO7 Career Development Award. KO7 CA113773. An interdisciplinary use of models for cancer prevention. \$367,623, **2006-2010**
4. Principal Investigator. McGill University. Cost-effectiveness of screening strategies for cervical cancer screening in Canada, Results of the CCAST trial, \$40,000; 2006-2007

5. Principal Investigator. CSL – Australia . Cost-effectiveness of adding an HPV 16 and 18 vaccine to screening in Australia. \$50,000, 2006
6. Co-Investigator. PI: Evan Myers. Merck Pharmaceuticals. Modeling the Effectiveness and Cost-effectiveness of an HPV Vaccine, \$160,000, 2005-2006
7. Co-Investigator. PI: Evan Myers Agency for Health Research and Quality. Genomics for Ovarian Cancer. \$126,234, 2005-2006,
8. Co-Investigator. PI: Joy Melnikow. National Cancer Institute. 1R01CA109142-01A1. Surveillance strategies following treatment for CIN. \$80,00 2005– 2008
9. Co-Investigator. PI: Sue Goldie. Gates Foundation-Harvard University. Vaccination and Screening to Prevent Cervical Cancer – a World-wide Analysis. \$36,289, 2005-2006
10. Co-Investigator. PI: Evan Myers. Sanofi Pasteur, MSD. Cost-effectiveness of adding HPV vaccination to screening in the UK, \$24,349, 2005
11. Co-Investigator. PI: Evan Myers. World Health Organization – Cost-effectiveness of vaccination to prevent infection with HPV compared to screening for cervical cancer in India. \$15,000. 2005
12. Co-Investigator. PI: Evan Myers. Agency for Health Quality and Research [Task Order 4]. Management of Adnexal Masses. \$250,000, 2004-2005
13. Co-Investigator. PI: Evan Myers. Merck Pharmaceuticals. Modeling the Effectiveness and Cost-effectiveness of an HPV Vaccine, \$150,000 2004-2005
14. Co-Investigator. PI: George Sawaya. Effectiveness and Cost-effectiveness of Cervical Cancer Screening in the Breast and Cervical Cancer Early Detection Program, \$300,000, 2002-2003
15. Co-Investigator. PI: David Matchar. Agency for Healthcare Research and Quality. Evidence-based Practice Center (EPC) Technical Support of the Center for Practice and Technology Assessment (CPTA) Technology Assessment Program. \$1,038,960, 2003-2007
16. Co-Investigator. PI: Laura Koutsky. National Cancer Institute [5R01CA034493-20]. Etiology and Natural History of Cervical Neoplasia, \$5,000,000, 2002-2007
17. Co-Investigator. PI: David Matchar. Agency for Healthcare Research and Quality. The Use of Positron Emission Tomography (PET) and Other Neuroimaging Techniques in the Diagnosis and Management of Alzheimer’s Disease and Dementia. \$149,848, 2001-2002
18. Co-Investigator. PI: Evan Myers. Merck Pharmaceuticals. Modeling the Effectiveness and Cost-effectiveness of an HPV Vaccine, \$203,306, 2001-2003

University Sources

1. Co-Investigator (PI: Eva Enns and Judith Kahn). University of Minnesota. \$74900. Integrating community-perspectives with decision modeling to address sexual health disparities in Greater Minnesota youth. 2013-2015
2. Principal Investigator. University of Minnesota. MMF-UMN Grant. \$22, 910. A survey to determine screening and human papillomavirus vaccination uptake between MN counties with varying rates of cervical cancer. 2012-2013
3. Principal Investigator. University of Minnesota. AHC Seed Grant. \$22, 399. Development of a simulation model for pertussis control in Dakota County, MN. 2009-2010
4. Principal Investigator. Joseph and Kathleen Bryan Alzheimer’s Disease Research Center, Duke University. Costs associated with increasing severity of Alzheimer’s Dementia, \$30,000, 2002-2003

Publications – Refereed Journals

1. Nelson E, Hughes J, **Kulasingam S**. Spatial patterns of human papillomavirus-associated cancers within the state of Minnesota, 1998-2007. *Spatial and Spatio-temporal Epidemiology*. In Press
Role: funding, conceptualization, critical review of the manuscript
2. Sainfort F, Kuntz KM, Gregory S, Butler M, Taylor BC, **Kulasingam S**, Kane RL. Adding decision models to systematic reviews: informing a framework for deciding when and how to do so. *Value Health*. 2013;16:133-9.
Role: critical review of the manuscript.
3. **Kulasingam S**, Havrilesky L, Ghebre R, Myers ER. A decision analysis for the USPSTF. JGLTD. *J Low Genit Tract Dis*. 2013;17:193-202
Role: funding, conceptualization, drafting of the manuscript
4. Canfell K, Chesson H, **Kulasingam SL** et al. Modeling Preventative Strategies against HPV-Related Disease in Developed Countries. *Vaccine*, 2012;30 Suppl 5:F157-67.
Role: critical review of the manuscript
5. Adegoke S, **Kulasingam S**, Virnig B. Cervical cancer trends in the United States: A 35 year population-based analysis. *J Women's Health*, 2012;21:1031-7
Role: conceptualization, critical review of the manuscript
6. Trikalinos T, **Kulasingam SL** et al. Chapter 10: Deciding Whether to Complement a Systematic Review of Medical Tests with Decision Modeling. *J General Internal Medicine*. *J Gen Intern Med*. 2012 Jun;27 Suppl 1:76-82
Role: conceptualization, critical review of the manuscript
7. Saslow D, Solomon D, Lawson HW, Killackey M, **Kulasingam SL**, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. *Am J Clin Pathol*. 2012;137:516-42. *CA Cancer J Clin*. 2012;62:147-72. *J Low Genit Tract Dis*. 2012
Role: Drafted section on screening intervals for cytology; critical review of the manuscript.
8. Havrilesky LJ, Sanders GD, **Kulasingam S**, Chino JP, Berchuck A, Marks JR, Myers ER. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. *Cancer*. 2011;117:545-53
Role: model development, critical review of the manuscript
9. Melnikow J, **Kulasingam S**, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF. Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. *Obstet Gynecol*. 2010;116(5):1158-70.
Role: conceptualization, implementation, analysis, drafting of methods and results, critical review of the manuscript

10. Kupperman M, Melnikow J; Slee S; Tancredi DJ; **Kulasingam S** et al., Preferences for Surveillance Strategies for Women Treated for High-Grade Precancerous Cervical Lesions. *Gynecologic Oncology*. **Gynecol Oncol**. 2010;**118(2):108-15**.
Role: conceptualization, critical review of the manuscript

11. Balasubramanian A, **Kulasingam SL**, Baer A, Hughes JP, Mao C, Kiviat NB, Myers ER, Koutsky LA. Accuracy and Cost-Effectiveness of Cervical Cancer Screening by High-Risk HPV DNA Testing of Self-Collected Vaginal Samples. *Journal of Lower Reproductive Tract Diseases*. **J Low Genit Tract Dis**. 2010;**14(3):185-95**.
Role: conceptualization, implementation, analysis, critical review of the manuscript

12. **Kulasingam SL**, Rajan R, St Pierre Y, Atwood CV, Myers ER, Franco EL. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. **BMC Med**. 2009;7:69.
Role: grant funding, conceptualization, implementation, analysis, manuscript Author

13. Saraiya M, Martinez G, Glaser K, **Kulasingam S**. Pap Testing and Sexual Activity among Young Women in the United States. *Obstetrics and Gynecology*. 2009;114:1213-9.
Role: conceptualization, implementation, critical review of the manuscript

14. Harris TG, Miller L, **Kulasingam SL**, Feng Q, Kiviat NB, Schwartz SM, Koutsky LA. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. *Am J Obstet Gynecol*. 2009;200:489.e1-8.
Role: implementation, analysis, critical review of the manuscript

15. Havrilesky LJ, Broadwater G, Davis DM, Nolte KC, Barnett JC, Myers ER, **Kulasingam S**. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. *Gynecol Oncol*. 2009;113:216-20.
Role: grant writing, conceptualization, implementation, critical review of the manuscript

16. Havrilesky LJ, Sanders GD, **Kulasingam S**, Myers ER. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? *Gynecol Oncol*. 2008;111:179-87.
Role: analysis, critical review of the manuscript

17. Baseman JG, **Kulasingam SL**, Harris TG, Hughes JP, Kiviat NB, Mao C, Koutsky LA. Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. *Am J Obstet Gynecol*. 2008;199:26.e1-8.
Role: conceptualization, critical review of the manuscript

18. Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, **Kulasingam S**; Gynecologic Oncology Group. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. *J Clin Oncol*. 2008;26:4144-50.
Role: conceptualization, implementation, analysis, critical review of the manuscript

19. **Kulasingam SL**, Bernard S, Barnabas RV, Llargeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. *Cost Effectiveness and Resource Allocation*. 2008;6:4-8.
Role: grant writing, conceptualization, implementation, analysis, manuscript writing
20. **Kulasingam SL**, Pagliusi S, Myers ER. Potential implications of non-adherence with cervical cancer screening in the era of HPV vaccination. *Vaccine*, 2007;25:8110-3
Role: conceptualization, implementation, analysis, manuscript writing
21. Jewel E, **Kulasingam SL**, Myers ER, Secord AA, Havrilesky L. Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. *Gyn Oncology*, 2007;107:532-40
Role: analysis, critical review of the manuscript
22. Havrilesky L, Secord AA, **Kulasingam SL**, Myers ER. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. *Gyn Oncology*. 2007 107:211-8
Role: analysis, critical review of the manuscript
23. Barnabas RV, **Kulasingam SL**. Economic Evaluations of human papillomavirus vaccines. *Expert Review of Pharmacoeconomics and Outcomes Research*, 2007;7:251-267
Role: conceptualization, implementation, analysis, manuscript writing
24. **Kulasingam SL**. Implementation of a successful human papillomavirus program. *Disease Management and Outcomes*. 2007;15:141-149
Role: conceptualization, implementation, analysis, manuscript writing
25. **Kulasingam SL**, Connolly L, Conway L, et al. The cost-effectiveness of adding an HPV vaccine to cervical cancer screening in Australia. *Sexual Health*, 2007;4:165-75
Role: conceptualization, implementation, analysis, manuscript writing
26. **Kulasingam SL**, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, Solomon D, Goldie SJ; ALTS Group. A cost-effectiveness analysis of the ASCUS and LSIL Triage Study. *J Natl Cancer Inst*. 2006;98(2):92-100.
Role: conceptualization, implementation, analysis, manuscript writing
27. **Kulasingam SL**, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Melnikow J, Washington AE, Sawaya GF. Cost-effectiveness of extending cervical cancer screening intervals in women with a history of normal Pap tests. *Obstet Gynecol*. 2006;107(2 Pt 1):321-8
Role: conceptualization, implementation, analysis, manuscript writing
28. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, **Kulasingam S**, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. *Int J Cancer*. 2006;119:1095-1101

- Role: analysis, critical review of the manuscript
29. **Kulasingam SL**, Samsa G, Matchar DB. Linking dementia research to policy: an example using FDG Positron Emission Tomography for the diagnosis of Alzheimer's Dementia and Mild Cognitive Impairment. *Am J Alzheimers Dis Other Demen.* 2006; 21:73-8. Bidus MA, Maxwell GL,
Role: conceptualization, implementation, analysis, manuscript writing
30. **Kulasingam S**, Rose GS, Elkas JC, Chernofsky M, Myers ER. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. *Obstet Gynecol.* 2006;107:997-1005.
Role: conceptualization, implementation, analysis, manuscript writing
31. Havrilesky LJ, **Kulasingam SL**, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. *Gynecologic Oncology* 2005;97:183-91.
Role: analysis, critical review of the manuscript
32. Orlando LA, **Kulasingam SL**, Matchar DB. A meta-analysis: Detection of pancreatic malignancy with positron emission tomography. *J Alimentary Pharmacology & Therapeutics.* 2005 20(10):1063-70.
Role: analysis, critical review of the manuscript
33. Matchar DB, Westermann-Clark EV, McCrory DC, Patwardhan M, Samsa G, **Kulasingam S**, Myers E, Sarria-Santamera A, Lee A, Gray R, Liu K; Agency for Healthcare Research and Quality. Dissemination of Evidence-based Practice Center reports. *Ann Intern Med.* 2005;21;142(12 Pt 2):1120-5.
Role: analysis, critical review of the manuscript
34. **Kulasingam SL**, Akiyama T, Mounsey JP, Ledingham R, Hallstrom AP; AVID Investigators. Lower observed versus expected (based on U.S. Age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias. *Pacing Clin Electrophysiol.* 2004;27:230-4
Role: conceptualization, implementation, analysis, writing manuscript
35. Harris TG, **Kulasingam SL**, Kiviat NB, Mao C, Agoff SN, Feng Q, Koutsky LA. Cigarette Smoking, Oncogenic HPV, Ki-67 Antigen, and Cervical Intraepithelial Neoplasia. *Am J Epi* 2004;159:834-842
Role: conceptualization, implementation, critical review of the manuscript
36. **Kulasingam SL**, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. *JAMA* 2003;290:781-789
Role: conceptualization, implementation, analysis, manuscript writing
37. Sawaya GF, McConnell KJ, **Kulasingam SL**, Lawson HW, Kerlikowske K, Melnikow J, Lee

- NC, Gildengorin G, Myers ER, Washington AE. Extending cervical cancer-screening intervals: excess risk and diagnostic tests. *NEJM* 2003; 349:1501-9
Role: implementation, analysis, critical review of the manuscript
38. **Kulasingam SL**, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, McCrory DC Schmechel DE, Matchar DB. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision-analysis. *Value in Health* 2003;6:542-550
Role: conceptualization, implementation, analysis, manuscript writing
39. Baer A, Kiviat NB, **Kulasingam S**, Mao C, Kuypers J, Koutsky LA. Liquid-based Pap smears without a transformation zone component: should clinicians worry? *Obstetrics and Gynecology* 2002;99:1053-9
Role: implementation, critical review of the manuscript
40. **Kulasingam SL**, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Evaluation of New Cervical Cancer Screening Technologies: Comparison of Sensitivity, Specificity, and Frequency of Referral. *JAMA* 2002;288:1749-57
Role: conceptualization, implementation, analysis, manuscript writing
41. Lampinen T, **Kulasingam S**, Min J, Borok M, Gwanzura L, Lamb J, Mahomed K, Woelk GB, Strand KB, Bosch ML, Edelman DC, Constantine NT, Katzenstein D, Williams MA. Detection of Kaposi's Sarcoma-Associated Herpes Virus (HHV8/KSHV) in Zimbabwean women. *J Infect Dis* 2000;181:1785-90.
Role: implementation, analysis, critical review of the manuscript
42. Brewer DD, Garrett SB, **Kulasingam S**. Forgetting as a cause of incomplete reporting of sexual and drug injection partners. *Sexually Transmitted Diseases* 1999;26:166-176.
Role: implementation, analysis, critical review of the manuscript

Publications – Non-Refereed

1. **Kulasingam SL** and Koutsky LA. Will new human papillomavirus diagnostics improve cervical cancer control efforts. *Curr Infect Dis Rep* 2001;3:169-182.

Non-authored Publications

1. AHRQ Evidence Practice Centers. White paper on Guidelines for Evidence Synthesis. April, 2009
2. National Breast and Cervical Cancer Early Detection Program Expert Panel. White paper on technologies for the early detection of cervical neoplasia. August, 2005

Other Publications – Published Scientific Technology Reviews

1. **Kulasingam SL**, Havrilesky LJ, Ghebre R, Myers ER. : A decision analysis for the United States Preventive Services Task Force. Prepared by the University of Minnesota and Duke University

- under Contract Nos. HHS-290-02-0025 and HHS-290-07-10064-I. Rockville, MD: Agency for Health Care Policy and Research, In Press
2. Kuntz K, Sainfort F, Butler M, Taylor B, Kulasingam S et al. Decision and Simulation Modeling in Systematic Reviews. Prepared by the University of Minnesota under Contract No. HHS-290-07-10064-I. Rockville, MD: Agency for Health Care Policy and Research.
 3. Myers ER, Havrilesky LJ, **Kulasingam SL** et al. Genomic Tests for Ovarian Cancer Detection and Management. Prepared by Duke University under Contract No. 290-02-0025. Rockville, MD: Agency for Health Care Policy and Research, December 2006.
 4. Myers ER, Bastian LA, Havrilesky LJ, **Kulasingam SL** et al. Management of Adnexal Mass. Prepared by Duke University under Contract No. 290-02-0025. Rockville, MD: Agency for Health Care Policy and Research, August 2005.
 5. Turner DA, Matchar DB, **Kulasingam SL**. A Horizon Scan of Procedural Interventions for the Treatment of Spine Conditions, including Neck, Thoracic and Back Pain and Associated Neurological Conditions. (Task Order No. 1. Prepared by Duke University under Contract No. 290-02-0025. Rockville, MD: Agency for Health Care Policy and Research, January 2005).
 6. Matchar DB, **Kulasingam SL**, Havrilesky L, Mann LO, Myers ER, McCrory DC, Patwardhan M and R Prosnitz. Positron emission testing for six cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular). (Task Order No. 0. Prepared by Duke University under Contract No. 290-02-0025. Rockville, MD: Agency for Health Care Policy and Research, March 2004).
 7. Matchar DM, **Kulasingam SL**, McCrory DC, Patwardhan MB, Rutschmann OT, Samsa et al. Use of Positron Emission Tomography and other neuroimaging techniques in the diagnosis and management of Alzheimer's disease and dementia. Task Order No. 7 (Prepared by Duke University under Contract No. 290-97-0014. Rockville, MD: Agency for Health Care Policy and Research, February 2002).

Contributed Papers Presented at Professional Meetings, Conferences

1. Havrilesky L, Secord A, **Kulasingam S**. Intraperitoneal versus intravenous chemotherapy for stage III ovarian cancer. The 38th Annual Meeting of the Society for Gynecologic Oncology. 2007
2. Havrilesky L, **Kulasingam S**, Sanders G, Myers E. Can Screening for Ovarian Cancer Achieve Mortality Reduction and be Cost Effective. The 38th Annual Meeting of the Society for Gynecologic Oncology. 2007
3. **Kulasingam S**, Myers E. Screening in the era of HPV vaccination: Will HPV tests perform better? 24th International Papillomavirus conference, Beijing, Nov 3-9, 2007
4. **Kulasingam SL**, Connelly L, Conway E, Hocking J et al. Are we underestimating the burden of disease in young women? Calibration of a type-specific HPV model to Australian National Registry data. In Proceedings of the 23rd International Papillomavirus conference, Prague, Czech Republic, Sept 1-7, 2006
5. Wain G, **Kulasingam SL**, Connelly L, Conway E et al. The case for prevention rather than cure - why vaccination against HPV is likely to be cost-effective in countries with successful screening programs. In Proceedings of the 23rd International Papillomavirus conference, Prague, Czech Republic, Sept 1-7, 2006
6. **Kulasingam SL**, Myers ER. A revised natural history model of human papillomavirus, cervical pre-cancer and cancer: implications for the cost-effectiveness of screening and

- vaccination. In Proceedings of the Society for Epidemiologic Research, Seattle, WA, June 2006
7. Sanders G, **Kulasingam S**, Havrilesky L, Myers E. Can screening ever be a feasible method for ovarian cancer detection? The 28th Annual Meeting of the Society for Medical Decision Making, 2006
 8. Tisci S, Bhatla N, Pagliusi S, Myers E, **Kulasingam S**. Is one cost-effectiveness model sufficient per country? A cost-effectiveness analysis of vaccination and screening for India. Proceedings of the 22st International Papillomavirus conference, Vancouver, Canada, April 30-May 6, 2005
 9. **Kulasingam S**, Bidus M, Maxwell L, Myers R. Cost effectiveness of adding HPV DNA testing to routine cervical cancer screening in a US army population. Proceedings of the 22st International Papillomavirus conference, Vancouver, Canada, April 30-May 6, 2005
 10. **Kulasingam SL**, Insinga R, Dasbach E, Myers ER. Research priorities for determining the health and economic impact of an HPV 6 and 11 vaccine. In: Proceedings of the 21st International Papillomavirus Conference; February 20-26, 2004; Mexico City, Mexico
 11. **Kulasingam SL**, Myers ER. What is the long-term efficacy of treatment for screen detected low and high-grade squamous intrapithelial lesion? Proceedings of the 21st International Papillomavirus Conference; February 20-26, 2004; Mexico City, Mexico
 12. **Kulasingam SL**, Matchar DM, Schmechel DE. Costs Associated With Increasing Severity of Dementia. Proceedings of the 9th International Conference on Alzheimer's Disease and Related Disorders, Philadelphia, PA July 17-22, 2004
 13. Baseman JG, **Kulasingam SL**, Harris TG, Hughes JP, Kiviat NB, Mao C, Koutsky LA. Evaluation of the DNA Pap test in primary screening for cervical neoplasia. In: Proceedings of the 15th International Society for STD Research Conference; July 27-30 2003; Toronto, Canada
 14. **Kulasingam SL**, Myers E Modeling a theoretical HPV vaccine: what happens to the predicted age-specific incidence curve when immunity wanes? In: Proceedings of the 5th EUROGIN Conference; April 13-16 2003; Paris, France
 15. **Kulasingam SL**, Myers E, Sung H, Kinney W, Miller M, Kearney K, Hiatt R, Sawaya G. Estimates of lifetime risk of cervical cancer using data from women with multiple negative Pap tests in a large pre-paid health plan. In: Proceedings of the 5th EUROGIN Conference; April 13-16 2003; Paris, France
 16. **Kulasingam SL**, Barnabas R, Garnett G, Myers ER. Accounting for transmission in Markov models of HPV infection and cervical cancer. In: Proceedings of the Symposium on Human Papillomavirus: Vaccines & Immunotherapies; July 10-13, 2003; Cambridge, England
 17. **Kulasingam S**, Harper DM, Tosteson AT, Myers ER. Impact of quality of life assumptions on cost-effectiveness of cervical cancer screening. In: Proceedings of the 20th International Papillomavirus Conference; October 4-9, 2002; Paris, France
 18. **Kulasingam SL**, McConnell J, Sawaya G, Myers ER. Effect of assumptions about the behavior of CIN 2 on predicted incidence of cervical cancer: possible age-related differences. In: Proceedings of the 20th International Papillomavirus Conference; October 4-9, 2002; Paris, France
 19. Sawaya GF, McConnell KJ, Kerlikowske K, Washington AE, Gildengorin G, Melnikow J, Lawson HW, **Kulasingam SL**, Myers ER. Paps and colposcopies to avert cervical

- cancer in well-screened women: annual versus screening 3 years later. In: Proceedings of the 20th International Papillomavirus Conference; October 4-9, 2002; Paris, France
20. **Kulasingam S**, Kiviat N, Myers ER, Hughes JP, Mao C, Koutsky LA. The cost-effectiveness of HPV DNA testing and cervical cytology for detection of CIN 2-3. In: Proceedings of the 18th International Papillomavirus Conference; July 24-28, 2000; Barcelona, Spain
 21. **Kulasingam SL**, Kiviat NB, Kuypers JM, Mao C, Hughes JP, Koutsky LA. Evaluation of screening strategies for detection of histologically confirmed CIN 2-3. In: Proceedings of the 18th International Papillomavirus Conference; July 24-28, 2000; Barcelona, Spain.

Invited Presentations at Professional Meetings, Conferences etc.

1. Kulasingam SL. Screening Interval for Cervical Cancer – A U.S. Perspective. HPV International, November, 2012. Puerto Rico
2. Kulasingam SL. Optimal Screening Intervals for Cervical Cancer. Invited Talk. ASCCP, March, 2012
3. Kulasingam SL. Molecular Testing Symposium sponsored by the National Cancer Institute, American Cancer Society, American Society for Colposcopy and CytoPathology and American College of Pathology. Invited Talk. November, 2011
4. Kulasingam SL. The respective public health impact of screening and vaccination: what the economic models tell us. EUROGIN, May, Portugal, 2011
5. Kulasingam SL. Screening with and without HPV vaccines. Plenary Session. 25th International Papillomavirus Conference, Montreal, Canada. May, 2010
6. Kulasingam SL. Using modeling to predict the optimal combinations of vaccination and screening. Malmo, Sweden, May, 2009
7. Kulasingam SL. Cost-effectiveness analyses of HPV vaccines. Clinical Sessions. 24th International Papillomavirus conference, Beijing, China. Nov 3-9, 2007
8. Kulasingam SL. Cost effectiveness of HPV Vaccines. *UICC World Cancer Congress 2006*. Bridging the Gap: Transforming Knowledge into Action. July 8-12, 2006, Washington, DC, USA
9. Kulasingam SL, Barnabas R, Bernard S, Myers ER. Adding a quadrivalent (6,11, 16 and 18 Types) human papillomavirus vaccine to the existing UK cervical cancer screening programme is potentially cost-effective. In Proceeding of the 14th European Society for Gynecologic Oncology. Istanbul, Turkey, September 25-29, 2005
10. Kulasingam SL. Effectiveness and Cost-Effectiveness of an HPV Vaccine. Public health Association of Australia. August, 2004
11. Society for Gynecologic Investigation. Natural history of HPV infection and cervical cancer. Houston, TX, 2004
12. Kulasingam SL, Myers ER. Combining Primary and Secondary Prevention – Adding an HPV vaccine to an Existing Screening Program. In: Proceedings of the 5th EUROGIN Conference; April 13-16 2003; Paris, France

Invited Lectures – Academic Institutions

- 2011 Masonic Cancer Center 2nd Annual Research Symposium, University of Minnesota.
- 2010 Comparative Effectiveness Research. P20 & Research Committee. University of Minnesota, School of Nursing.
- 2008 Decision Modeling to inform Cervical Cancer Research Priorities, University of Washington, Seattle, Washington

- 2007 Insights from decision modeling regarding HPV vaccines and cervical cancer screening. Johns Hopkins University, Baltimore, MD
- 2007 Effectiveness and Cost-effectiveness of different Screening Strategies in Canada. McGill University. Montreal, Canada
- 2003 Epidemiology Journal Club, University of North Carolina, Chapel Hill, North Carolina

TEACHING AND ADVISING

University of Minnesota

Courses Taught

PUBH 6341 Epidemiologic Methods 1 (2010-2013). This course enrolls 55 to 60 students each semester and is one of two sections of the required first methods course for Epidemiology PhD and Master's students.

May Short course in infectious disease modeling (2009)

Masters Theses Directed

Jeremy Bikah, December 2013. Cost Effectiveness Analysis of a Targeted Vaccination Reminder/Recall Letters Program in Areas of Persistent Low Immunization Coverage in Minnesota

Erinn Sanstead, June 2012. An agent based model for estimating pertussis outbreaks in Dakota County MN.

Kazihuko Akasaka, August 2012. Estimating past (1985 to 2009) and future (2010 to 2029) trends in HIV incidence and prevalence in Japan. An application of back-calculation estimation methods.

Rachel Mlodzik, May 2012. A descriptive study of pertussis incidence trends in Dakota County, MN from 1996 to 2008.

Melissa MacMahon, May 2012. Clinical Predictors for Laboratory-Confirmed Cases of Pertussis in Dakota and Ramsey Counties, Minnesota, 2004-2009

Erik Nelson, MPH, June 2010

Use of Geographic Information System approaches to determine the burden of HPV infections in the US

Hilarie Martin, MPH, September 2010. Characterizing the pertussis epidemic curves for 2003-4 and 2008-9 for Dakota County, MN.

Hilary Whitham, MPH, June, 2009. Risk estimation for cancer guideline development

Masters Theses Advised

Elizabeth Schiffman, January, 2014. Observation and risk assessment of animal/human interactions at petting zoos in Minnesota

Delia Winters (CHE), May 2012. The Association between Venue-specific Drug Use and Unprotected Anal Intercourse among Men who have Sex with Men

Sola Adegoke (HPA), June 2011. Trends in cervical cancer incidence using SEER data.

Chia-hsuan Li, MS (HPA), June 2010. Colorectal cancer screening in Taiwan.

Zoya Geissina, MS (Environmental Health), June 2009. Epidemiologic and demographic transitions in Malaysia and Singapore, 1995-2005

Doctoral Students Advised

Hilary Whitham. 2009- Present. Epidemiology and Community Health. Cost-Effective Approaches for Cervical Cancer Prevention in HIV+ women in Senegal.

Erik Nelson. 2011-Present. Epidemiology and Community Health. Use of spatial statistics and internet surveys to identify disparities in HPV vaccination and cancer screening in Minnesota.

Doctoral Committees Served On

Bart Abban, PhD, 2009-Present, Division of Health Policy . Health disparities in colorectal cancer.

Kristin Sweet, PhD. 2012- Present, Division of Health Policy. Predicting the Burden of Hepatitis C in the US using epidemiology and decision modeling.

Duke University

Courses Taught

Duke Clinical Research Training Program, Health Economics – Cost-Effectiveness Decision Models

Society for Medical Decision Making. Using mathematical models to inform policy decisions. (Short Course. SMDM Atlanta, GA)

Doctoral Committees Served on

Akhila Balasubramanian, PhD, June 2008. University of Washington. The role of self-collected HPV DNA samples in screening for cervical neoplasia

SERVICE TO THE DISCIPLINE

2014	NIH – NCI - Reviewer – K01 and K22 Review
2011-Present	Associate Editor, BMC Cancer
2011-Present	AHRQ HEOR Study Section Member
2010-12	Co-Chair – Molecular Markers for Cervical Cancer – Screening Intervals. ACS-ACP-ASCCP
2009	European Union Commission. 7th Framework Programme for Research, Technological Development and Demonstration
2009	Agency for Health Quality and Research– co-authored white paper on use of decision modeling for evidence-based practice.
2006-2010	Centers for Disease Control. External consultant for determining appropriate use of HPV DNA tests for the BCCEDP population.
2011	NIH – Reviewer – Economics of Prevention study section
2010-11	AHRQ – Ad hoc member – HCQER study section
2009	AHRQ – Reviewer – Special Emphasis Panel

SERVICE TO THE UNIVERSITY/COLLEGE/DEPARTMENT

Department Service

2012-13	PhD Admissions Committee
2010-13	PhD Part B Committee
2009-12	MPH Admissions Committee
2009-10	PhD Part A Committee
University Service	
2013-Present	MD-PhD Admissions Committee
2011-Present	Gynecologic Oncology Translational Research Group

